Natco PharmaNSE:NATCOPHARM +1.28%89 EBITDA Margin % is 27.79% as of Mar. 2026, which is 34% below its 10-year median of 42.13. GuruFocus rates NSE:NATCOPHARM with a GF Score™ of 89/100 and a GF Value™ of ₹941.93 (Fairly Valued). The stock has 2 warning signs investors should review. Among 952 Drug Manufacturers companies, Natco Pharma ranks better than 95.06% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Natco Pharma's EBITDA for the
three
months ended in Mar. 2026 was ₹2,054 Mil. Natco Pharma's Revenue for the
three
months ended in Mar. 2026 was ₹7,391 Mil. Therefore, Natco Pharma's EBITDA margin for the quarter that ended in Mar. 2026 was 27.79%.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Natco Pharma EBITDA Margin % Related Terms
Natco Pharma EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Natco Pharma's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NSE:NATCOPHARM vs ZTS, UTHR: EBITDA Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Natco Pharma's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Natco Pharma EBITDA Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Natco Pharma's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Natco Pharma's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Natco Pharma (NSE:NATCOPHARM) has a EBITDA Margin % of 27.79% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Natco Pharma and its competitors. This is 34% below median its historical median of 42.13. Over the past decade, Natco Pharma's EBITDA Margin % has ranged from 18.79 to 57.58. According to the industry distribution chart, Natco Pharma ranks #47 out of 952 companies in the Drug Manufacturers industry, placing it in the top 4.9%.
Is Natco Pharma's EBITDA Margin % too high?
Natco Pharma's current EBITDA Margin % of 27.79% is 34% below median its 10-year median of 42.13. Over the past 10 years, this metric has ranged from a low of 18.79 to a high of 57.58. The Drug Manufacturers industry median EBITDA Margin % is 12.47. Natco Pharma's value of 27.79% is 122.9% above this industry median. Based on the distribution chart, Natco Pharma ranks #47 out of 952 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Natco Pharma has a GF Score™ of 89/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Natco Pharma's EBITDA Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Natco Pharma ranks #47 out of 952 companies for EBITDA Margin %. This places Natco Pharma in the top 5% of its industry — outperforming the majority of peers. The industry median EBITDA Margin % is 12.47. Natco Pharma's value of 27.79% is 122.9% above this benchmark. Historically, Natco Pharma's own EBITDA Margin % has ranged from 18.79 to 57.58 over the past decade. While the company's 10-year median is 42.13 vs. the industry median of 12.47, Natco Pharma has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Drug Manufacturers company?
The median EBITDA Margin % among Drug Manufacturers companies is 12.47, based on 952 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Natco Pharma's current EBITDA Margin % of 27.79% is 122.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Natco Pharma and its competitors. For the Drug Manufacturers industry, the median EBITDA Margin % is 12.47 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Natco Pharma's current EBITDA Margin % is 27.79%, which is 34% below median its own 10-year median of 42.13. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Natco Pharma stock overvalued right now?
Based on GuruFocus' analysis, Natco Pharma (NSE:NATCOPHARM) is currently considered Fairly Valued. The stock's GF Value™ is ₹941.93, compared to a current price of ₹931.30 — trading 1.1% below its estimated fair value. The current EBITDA Margin % is 27.79%, which is 34% below median its 10-year median of 42.13 and 122.9% above the Drug Manufacturers industry median of 12.47. Natco Pharma's overall GF Score™ is 89/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Natco Pharma (NSE:NATCOPHARM), the current EBITDA Margin % is 27.79% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Natco Pharma (NSE:NATCOPHARM) Overvalued in 2026?
Based on GuruFocus' analysis, Natco Pharma stock appears to be undervalued.
The current stock price of ₹931.30 is trading 1.1% below its estimated GF Value™ of ₹941.93.
GuruFocus considers Natco Pharma to be Fairly Valued.
Key valuation signals for NSE:NATCOPHARM:
EBITDA Margin %: 27.79% (34% below median its 10-year median of 42.13)
GF Value™: ₹941.93 vs. price of ₹931.30 (1.1% below fair value)
Industry Position: 122.9% above the Drug Manufacturers median (#47 of 952)
No single metric tells the full story. See the NSE:NATCOPHARM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Natco Pharma Ltd is a drug manufacturing company. Natco aims to make specialty medicines accessible to all by manufacturing niche pharmaceutical products backed by its research and development capabilities. While the vast majority of the company's revenue is generated in India, the company looks internationally for growth opportunities. The company maintains a presence in Oncology and Hepatology treatment areas. Natco's active pharmaceutical ingredient segment APIs forms a core part of the company's business. The company operates in two different business segments: pharmaceuticals and agrochemicals. It derives maximum revenue from Pharmaceuticals Segment.
89GF Score
Get the complete analysis for NSE:NATCOPHARM
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:NATCOPHARM has been successfully added to your 
